Zealand Pharma A/S (CPH:ZEAL)
Denmark
· Delayed Price · Currency is DKK | Market Cap | 28.70B |
| Revenue (ttm) | 62.69M |
| Net Income (ttm) | -1.08B |
| Shares Out | 70.68M |
| EPS (ttm) | -16.24 |
| PE Ratio | n/a |
| Forward PE | 11.60 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 348,945 |
| Average Volume | 370,221 |
| Open | 409.60 |
| Previous Close | 396.50 |
| Day's Range | 400.00 - 417.00 |
| 52-Week Range | 380.20 - 972.00 |
| Beta | 0.58 |
| RSI | 34.78 |
| Earnings Date | May 8, 2025 |
About Zealand Pharma
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglu... [Read more]
Financial Performance
In 2024, Zealand Pharma's revenue was 62.69 million, a decrease of -81.71% compared to the previous year's 342.79 million. Losses were -1.08 billion, 53.3% more than in 2023.
Financial StatementsNews
Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery
Press release – No. 5 / 2025 Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery Utpal joins Zealand Pharma at a pivotal moment as i...
Zealand Pharma (ZLDPF) Launches 2025 Incentive Program | ZLDPF Stock News
Zealand Pharma (ZLDPF) Launches 2025 Incentive Program | ZLDPF Stock News
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Company announcement – No. 10 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhag...
Zealand Pharma launches long-term incentive programs for Zealand Pharma's Board of Directors, Corporate Management and employees for 2025
Company announcement – No. 9 / 2025 Zealand Pharma launches long-term incentive programs for Zealand Pharma's Board of Directors, Corporate Management and employees for 2025 Copenhagen, Denmark, April...
Zealand Pharma Goes on Hiring Spree as It Gears Up for Obesity Tie-Up With Roche
The Danish biotech's recruitment drive began last summer when data from an early-stage trial of the drug—petrelintide—showed its potential.
Resolutions from Zealand Pharma's Annual General Meeting 2025
Company announcement – No. 7 / 2025 Resolutions from Zealand Pharma's Annual General Meeting 2025 Copenhagen, Denmark, March 27, 2025 - Zealand Pharma A/S ("Zealand") (Nasdaq: ZEAL) (CVR-no.
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
Company announcement – No. 6 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
Company announcement – No. 5 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, March 20, 2025 – Zealand Pharma A/S (“Zealand”) (NA...
Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
Press release – No. 4 / 2025 Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Initiated in December 2024, the Phas...
Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal
Zealand Pharma's new drug petrelintide will help people lose weight: CEO
Zealand Pharma CEO Adam Steensberg discusses the company's new collaboration and licensing agreement with Roche as well as the commercial opportunities for its amylin analog molecule.
Roche agrees biggest-ever obesity drug deal
Swiss pharma group signs $5.3bn licensing agreement for next-generation treatment made by Zealand Pharma
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion
Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.
Roche And Zealand Team Up To Develop Petrelintide
Roche partnered with Zealand Pharma to co-develop and co-commercialize petrelintide, a novel amylin analog. Roche gains the most advanced amylin analog that is available and strengthens its obesity pi...
Roche Further Boosts Obesity Pipeline With Zealand Pharma Deal Worth $5.3 Billion For Weight Loss Drugs
Roche Holdings AG (OTC: RHHBY) confirmed a licensing agreement with Zealand Pharma on Wednesday that will see the two companies co-develop petrelintide . Petrelintide is Zealand Pharma's amylin analo...
New drug candidate will help people lose weight in an easier way, Zealand Pharma CEO says
Zealand Pharma CEO Adam Steensberg discusses the companys new collaboration and licensing agreement with Roche as well as the commercial opportunities for its amylin analog molecule.
Roche, Zealand Pharma in $5.3 billion pact for obesity drugs
Roche Holding licensed a new weight-loss drug from Zealand Pharma, bolstering the drugmaker’s effort to get into a hot market dominated by Novo Nordisk and Eli Lilly & Co.
Roche and Zealand Pharma strike $5.3 billion deal for new obesity drug candidate
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand Pharma's obesity drug candidate.
Roche takes big step in weight-loss field with $5.3 billion deal.
Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to Zealand Pharma in a licensing and development deal.
Roche, Zealand Pharma enter $5.3B license deal for obesity treatment
Roche to develop, commercialize obesity drug with Zealand Pharma
Roche has entered an exclusive collaboration and licensing agreement with Danish obesity drug maker Zealand Pharma to co-develop petrelintide as an obesity therapy drug, the Swiss company said on Wedn...
Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and obesity
Company announcement – No. 4 / 2025 Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with ...
Roche enters into an exclusive collaboration & licensing agreement with Zealand Pharma to co-develop and co-commercialise petrelintide as a potential foundational therapy for people with overweight and obesity
Basel, 12 March 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma (Nasdaq Copenhagen: ZEAL) (CVR...